Cancer cure for 32 cancer types: results from the EUROCARE-5 study

Abstract Background Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods 7.2 million cancer patients (42 population-based cancer registries in 17 European...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of epidemiology 2020-10, Vol.49 (5), p.1517-1525
Hauptverfasser: Dal Maso, Luigino, Panato, Chiara, Tavilla, Andrea, Guzzinati, Stefano, Serraino, Diego, Mallone, Sandra, Botta, Laura, Boussari, Olayidé, Capocaccia, Riccardo, Colonna, Marc, Crocetti, Emanuele, Dumas, Agnes, Dyba, Tadek, Franceschi, Silvia, Gatta, Gemma, Gigli, Anna, Giusti, Francesco, Jooste, Valerie, Minicozzi, Pamela, Neamtiu, Luciana, Romain, Gaëlle, Zorzi, Manuel, De Angelis, Roberta, Francisci, Silvia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. Methods 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. Results LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and
ISSN:0300-5771
1464-3685
DOI:10.1093/ije/dyaa128